Psoriatic arthritis is associated with an additional increase in cardiovascular disease. One hypothesis shows that rheumatic diseases and atherosclerosis may be related due to an inflammatory mechanism.
The European League Against Rheumatism and the American College of Rheumatology have published treatment recommendations for polymyalgia rheumatic, the most common inflammatory musculoskeletal disease of older people.
A Clinical and Experimental Rheumatology review offers a critical analysis of recent studies on systemic sclerosis to best classify and manage this chronic condition.
Tofacitinib, an RA approved drug, shows promise for PsA.
Autoantibodies against carbamylated proteins in Sjögren’s syndrome could be used as a new biomarker.
Study shows that patients with psoriatic arthritis and cutaneous psoriasis could be good candidates for total hip replacement.
Developing arthritis increases the risk of falling into poverty, especially for women, a new study shows.
Evidence-based medicine and patient input needed in prescribing bisphosphonates for osteoporosis.
Two chemical messengers are the targets of several new drugs that are in clinical trials or approved for treating psoriasis and other autoimmune diseases
Ambrisentan and tadalafil as one lowers risk of clinical failure in patients with pulmonary arterial hypertension.